EPCAM Recombinant Monoclonal Antibody

1. This research demonstrates a novel approach utilizing a combination of EpCAM and FRalpha as targets for CTC capture, significantly enhancing the sensitivity and efficiency of CTC detection in non-small cell lung cancer (NSCLC). PMID: 29352248
2. This review explores the multifaceted functions of EpCAM in physiological processes and various diseases. PMID: 30015855
3. Our findings suggest that GA733-2-Fc conjugated with the ER-retention motif KDEL is a more effective antigen for preventing tumor growth induced by colorectal carcinoma while minimizing allergic responses. PMID: 30249898
4. Extracellular vesicles tend to localize in the intestinal tract, associating with epithelial cell adhesion molecule. PMID: 27721471
5. Overexpression of EpCAM and melan-A is linked to malignant melanoma. PMID: 29076925
6. Quercetin has been shown to suppress breast cancer stem cell proliferation, self-renewal, and invasiveness. It also reduces the expression of proteins associated with tumorigenesis and cancer progression, such as aldehyde dehydrogenase 1A1, C-X-C chemokine receptor type 4, mucin 1, and epithelial cell adhesion molecules. PMID: 29353288
7. Adenocarcinomas exhibited significantly higher staining scores for both VEGF and alphaSMA compared to squamous cell carcinomas. In 42 cases with high CD31 scores, patients with lung cancer showing mature tumor vessels had a significantly better five-year survival rate (87%) compared to those with immature tumor vessels (69%). PMID: 29970536
8. A novel EPCAM founder deletion causing Lynch Syndrome has been identified in the Polish population. PMID: 28369810
9. This review provides updated insights into the EpCAM field, simplifying the understanding of its biological role and showcasing promising therapeutic tools developed using antibodies and vaccines for various cancer types with the aim of improving patient outcomes. PMID: 29759567
10. This is the first demonstration that the low sensitivity of CellSearch(R) in detecting circulating tumor cells in colorectal cancer patients is not attributed to the lack of EpCAM. PMID: 28604994
11. Data suggest that epithelial cell adhesion molecule (EpCAM) can serve as an additional marker for distinguishing cystic lesions in the sellar region. PMID: 27431859
12. Data indicate that epithelial cell adhesion molecule (EpCAM) demonstrates high tumor distinctiveness. PMID: 28820475
13. Low expressions of Oct4-EpCAM in IHC and CD133 in qPCR may reveal roles in gastric cancer. PMID: 27557490
14. EpCAM expression contributes to tumor resistance to chemotherapy in patients with ovarian cancer. PMID: 28574829
15. The current findings suggest that Ep-CAM expression may be associated with CRC carcinogenesis, while its loss is correlated with the progression, metastasis, and poor prognosis of CRC. Ep-CAM expression may be a valuable biomarker for the clinical diagnosis of CRC. PMID: 28558958
16. This study identified a positive correlation between EpCAM and COX-2 expression in breast cancer cell lines and tissue specimens. EpCAM and COX-2 were associated with the prognosis of breast cancer patients. PMID: 28393249
17. CD133+ cells exhibited genetic heterogeneity among patients without any defined profile compared to CD133-/EpCAM+ cells. PMID: 28347289
18. Combining targets like E-cadherin, epithelial membrane antigen (EMA), human epidermal growth receptor type 2 (Her2/neu), and carcinoembryonic antigen (CEA) resulted in nearly 100% detection of ductal ovarian metastases, while the combination of EMA, Her2/neu, and epithelial cell adhesion molecule (EpCAM) proved most effective for detecting lobular ovarian metastases. PMID: 28327103
19. Whole-genome sequencing identified the homozygous intronic variant EPCAM c.556-14A>G, considered explanatory for the patient's intractable diarrhea and providing a diagnosis of congenital tufting enteropathy. PMID: 28701297
20. Low EPCAM expression is associated with colorectal carcinoma. PMID: 26528695
21. Our study provided clinical evidence for EpCAM intracellular domain as a predictor of cancer development in patients with oral dysplasia and recurrence in oral squamous cell carcinoma patients. PMID: 27421772
22. Elevated epithelial cell adhesion molecule EpCAM (mRNA+) CTC and Treg/CD4(+) levels were associated with early recurrence of hepatocellular carcinoma (HCC), indicating a poor clinical outcome. PMID: 27439521
23. These observations offer valuable insights into the regulation of EpCAM expression during EMT, demonstrating an unexpected role for EpCAM in regulating ERK and defining a novel double-negative feedback loop between EpCAM and ERK that contributes to the regulation of EMT. PMID: 28192403
24. This study highlights the potential of an EpCAM-specific NIR-fluorescent agent in combination with a clinically validated intraoperative imaging system to visualize various tumors during surgery. PMID: 27842504
25. The studies identified the characteristics and function of EpCAM glycosylation sites on breast cancer cell adhesion. PMID: 28315854
26. These results identify EpCAM as a substrate of matriptase and link HAI-2, matriptase, EpCAM, and claudin-7 in a functionally important pathway that causes disease when dysregulated. PMID: 28094766
27. The EpCAM aptamer conjugated NCS demonstrated specificity to EpCAM-positive cells. PMID: 28668853
28. Pseudomyxoma peritonei ubiquitously express CEA and EpCAM. PMID: 27038681
29. This research explores the relationship between EpCAM-regulated transcription and altered biophysical properties of cells that promote epithelial-mesenchymal transition (EMT) in advanced endometrial cancer. PMID: 27569206
30. This study employed a next-generation sequencing (NGS) approach. NY-SAR-35 expression induced growth, proliferation, metastasis, and stemness genes, as indicated by the up-regulation of CXCR4, EpCAM, CD133, and CD44 at both mRNA and protein levels. PMID: 28126340
31. These results indicate that adipocyte-secreted factors might regulate cancer stem cell behavior through several signaling molecules, including c-Met, STAT3, and ERK1/2. Inhibition of these signaling pathways offers novel strategies for targeting the effects of adipose-derived cytokines in cancer. PMID: 27131739
32. The meta-analysis revealed that the expression of EpCAM in the gastric cancer group was higher than in the control group. Moreover, EpCAM overexpression was associated with larger tumor size, lymph node metastasis, and a worse prognosis in gastric cancer. [review] PMID: 28403178
33. The expression of EpCAM(MT) is associated with a more aggressive phenotype and predicts poor survival in patients with colorectal cancer. PMID: 26996277
34. Higher levels of epithelial cell adhesion molecule (EpCAM) in breast cancer may be associated with a poor response to neoadjuvant chemotherapy (NAC) via a potential chemoresistant effect. PMID: 27041736
35. By monitoring the change in fluorescence signal, the target EpCAM protein could be detected sensitively and selectively with a linear detection range from 3nM to 54nM and a limit of detection (LOD) around 450pM. This nanobiosensor has been successfully utilized for EpCAM-expressed breast cancer MCF-7 cell detection. PMID: 27614683
36. EpCAM, CD44, and CD133 expression could be potential markers for Barrett esophagus disease progression. PMID: 28216140
37. These findings provide important insights into the regulation of epithelial cell adhesion molecule apoptosis and suggest epithelial cell adhesion molecule as a potential target for the treatment of breast cancer. PMID: 28349835
38. Epithelial cell adhesion molecule exhibited a distinct expression pattern among salivary gland neoplasms and in different grades of mucoepidermoid carcinomas. PMID: 27649957
39. Our research concluded that the peptide could be a better supplement to the EpCAM antibody for capturing circulating tumor cells (CTCs) in a microfluidic system with a broader spectrum. PMID: 27818051
40. This study presents a molecular characterization of congenital tufting enteropathy in Italian patients, identifying three mutations in the EpCAM gene. PMID: 26684320
41. EpCAM serves as a potential biomarker of prognostic significance that could be used to identify oral squamous cell carcinoma patients at high risk and predict patient survival. PMID: 26401964
42. Findings indicate that the EGF-like domain of EpCAM is cleaved off in cancer cells that have undergone epithelial-mesenchymal transition. PMID: 26775583
43. Based on these results, it can be concluded that EpCAM is suitable for use as an EC biomarker, therapeutic target, and effective parameter for tumor transfer and prognosis evaluation by aptamer SYL3C staining. PMID: 26687301
44. CHD4 was abundantly expressed in EpCAM(+) hepatocellular carcinoma with the expression of hepatic stem cell markers and a poor prognosis in two independent cohorts. PMID: 26095183
45. Flow cytometry assay revealed that doxorubicin exposure decreased EpCAM-positive cell quantities in three HCC cell lines. EpCAM siRNA knock-down attenuated cell mortality after doxorubicin exposure. PMID: 26984381
46. EpCAM-based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except those with low claudin expression. PMID: 26556851
47. Increased Expression of EPCAM mRNA is associated with Recurrence After Curative Resection of Hepatocellular Carcinoma. PMID: 25791790
48. This research revealed a new molecular mechanism of MTA1-mediated invasion and metastasis in lung cancer through its downstream target EpCAM. Interfering with EpCAM function may be a novel therapeutic strategy for treating MTA1-overexpressing lung carcinoma. PMID: 26698569
49. Knockdown of EpCAM can inhibit breast cancer cell growth and metastasis by inhibiting the Ras/Raf/ERK signaling pathway and MMP-9. PMID: 26356670
50. Results indicate that the anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody could potentially be used for cancer-targeted therapy. PMID: 26317650

Show More

Hide All

HGNC: 11529

OMIM: 185535

KEGG: hsa:4072

STRING: 9606.ENSP00000263735

UniGene: Hs.542050